May 30, 2025 09:46 AM EDT
Financing
Deals
Pharma

As a chal­leng­ing first half nears a close, bio­phar­ma un­cer­tain­ty per­sists

Kyle LaHucik

Biotech Correspondent

What will the sec­ond half of 2025 bring for bio­phar­ma?

It’s a tough ques­tion to an­swer af­ter a slog of stock-mov­ing pro­pos­als out of Wash­ing­ton …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times